The Future of Respiratory Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

03 Jun 2010 • by Natalie Aster

GBI Research “The Future of Respiratory Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis” essentially provides insights on the respiratory market’s potential, actual sales, actual volume and price forecasts to 2015. The report also delves deep into the respiratory market potential in various indications such as pulmonary hypertension, cystic fibrosis, asthma, and Chronic Obstructive Pulmonary Disease (COPD), and provides insights into the respiratory disease R&D pipeline. The report also elucidates the respiratory disease’s competitive landscape including the benchmarking of leading companies. Finally, key trend analysis on mergers and acquisitions, and licensing agreements involving respiratory disease therapeutics are also provided.

Patent Expiries Coupled with Generic Competition are Negatively Impacting the Market Pulling it down to CAGR 2.8% in 2009-2015 from CAGR 11%in 2000-2008.

The Global Respiratory Therapeutics market was valued to be worth $20.1 billion in 2008 and is expected to rise in revenues to $24.5 billion with a Compound Annual Growth Rate (CAGR) of 2.8% by 2015. In 2008, approximately 23.5 million patients received pharmacological treatment for their respiratory diseases with the average cost of therapy being $4,160 per year. The patient volume appears to be increasing at a significant rate of 5% per year. In addition, the average annual cost of therapy for the respiratory diseases therapeutic area appears to be increasing at a gradual rate over the next one year with an expected slight price decline from 2010 onwards. As a result, the respiratory disease market growth rate is going to see a decline during 2008 – 2015.

High Unmet Need across all Indications of Respiratory Therapeutic Market.

Respiratory disease disorders such as asthma and COPD are currently some of the most explored therapeutic areas while cystic fibrosis and pulmonary hypertension are some of the least explored. The market consists of several drugs with high safety levels. The cystic fibrosis market and pulmonary hypertension is in need of an effective replacement for current therapy to streamline long-term treatment.

Top Five Companies Contributed to 48% of the Global Sales in 2008.

GlaxoSmithKline (GSK) is the market leader with 21% market share which accounted for $8.3 billion in 2008 of the respiratory therapeutics sector. Merck, with an approximate market share of 12%, accounted for $4.9 billion to the market. Astrazeneca contributed approximately $3.8bn to the market cutting a share of approximately 10%. Novartis holds a market share of 3%. Other major players within the market included Sanofi-Aventis and Sepracor which contributed approximately 3% of the respiratory therapeutics market.

In 2007-2008, 67% of Deals were Worth Less than $200m

Most number of Merger and acquisitions deals in the respiratory therapeutics market were worth less than $200m with a 67% share of the total number of deals. The market has witnessed numerous strategic consolidations in the past two years. The US market witnessed the highest number of acquisitions at various levels. The total value of M&A deals within the global respiratory therapeutics market was approximately $2.7 billion dollars in 2008. The highest value deal was when Reckitt Benckiser acquired Adams Respiratory for an approximate $2.3 billion.

About GBI Research

GBI Research is a leading business information company providing global business information reports and services.

Our highly qualified team of Analysts, Researchers, and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyze and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.